The Diagnostic Value of miR-155 Expression in the Serum of Patients with Breast Cancer According to Molecular Subtypes of Breast Cancer

Shooshtarian, Bentolhoda; Mohammadi-Asl, Javad; Kohan, Lila

doi:10.5812/jjhr.59937

Cited by 4 publications

(5 citation statements)

References 26 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the expression of miR-155 in BC patients was 1.68 ± 0.66 times more than that in the control group. This finding was in line with the results of the previous studies that reported increased miR-155 expression by 2.62 to 8.8-fold in breast cancer patients compared to controls [ 16 ]. In the studies of Guo et al [ 15 ], Sun et al [ 17 ], and Zhang et al [ 18 ], the increase in miR-155 expression in BC was 2.94 times, 2.62 times, and 2.87 times, respectively.…”

Section: Discussionsupporting

confidence: 93%

Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer

Mojahed

Aalami

Pouresmaeil

et al. 2020

International Journal of Genomics

View full text Add to dashboard Cite

Aim. Biochemical markers, including microRNAs (miRs), may facilitate the diagnosis and prognosis of breast cancer. This study was aimed at assessing serum miR-155 expression in patients with breast cancer and receptors. Methods. This case-control study was conducted on 36 patients with breast cancer and 36 healthy individuals. After RNA extraction from the patient’s serum, cDNA was synthesized. The expression of miR-155 was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software. Results. The mean age of subjects in breast cancer and control groups was 47.64±8.19 and 47.36±7.52 years, respectively. The serum miR-155 expression was higher in the cancer group (1.68±0.66) compared to the control group (p<0.0001). There was a significant relationship between serum miR-155 expression and the tumor grade (p<0.001), tumor stage (p<0.001), and tumor size (p<0.001) of the patients. However, no relationship between miR-155 expression and the presence of lymph node involvement (p=0.15), HER2 (p=0.79), Ki-67 (p=0.9), progesterone receptor (p=0.54), and estrogen receptors (p=0.84) was found. The ROC curve analysis showed that the AUC was 0.89 (77.78% sensitivity and 88.89% specificity), and the cutoff was 1.4 (Youden index: 0.6667) for detecting breast cancer. Conclusion. The findings of this study revealed that serum miR-155 may serve as a potential noninvasive molecular biomarker for breast cancer diagnosis and can help predict the grade of the disease.

show abstract

Section: Discussionsupporting

confidence: 93%

Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer

Mojahed

Aalami

Pouresmaeil

et al. 2020

International Journal of Genomics

View full text Add to dashboard Cite

show abstract

“…showed that circulating miR‐140 could be used as a biomarker for breast cancer screening and progression with an AUC of 0.69, a sensitivity of 73% and a specificity of 50% 17 . In another study, miR‐155 had a considerable diagnostic accuracy in patients with molecular subtypes (Luminal A, Luminal B and Triple negative group) of breast cancer 26 . Xu et al 27 .…”

Section: Discussionmentioning

confidence: 99%

Circulating status of microRNAs 660‐5p and 210‐3p in breast cancer patients

Nashtahosseini

Aghamaali

Sadeghi

et al. 2021

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background MicroRNAs (miRs), which are stable in the blood, comprise small non‐coding RNAs that regulate gene expression. They have important roles in almost all biological pathways, especially in cancer‐relevant processes, and have an abnormal expression in breast cancer. In recent studies, the aberrant expression level of various microRNAs has been demonstrated in human cancer. In the present study, the status of serum microRNA‐210‐3p and microRNA‐660‐5p expression levels in breast cancer patients was determined compared to healthy controls. Methods Serum samples were collected from 40 newly diagnosed breast cancer patients and 40 healthy controls. A real‐time quantitative polymerase chain reaction was utilized to detect the expression levels of these microRNAs. Data analysis was conducted with p < 0.05 being considered statistically significant. Results The data obtained showed that serum levels of miR‐660‐5p and miR‐210‐3p were significantly up‐regulated in breast cancer patients compared to healthy controls (p < 0.001 and p = 0.001, respectively). In addition, significant up‐regulation was observed in the early stage (in situ, stage I and II) of breast cancer patients (n = 25) compared to healthy (n = 40) controls (p < 0.001 and p < 0.05, respectively). Receiver‐operating characteristic curve analysis indicated that the serum miR‐660‐5p and miR‐210‐3p levels have reasonable sensitivity (79% and 68%) and specificity (61% and 51%) for the detection of breast cancer patients (area under the receiver‐operating curve = 0.774 and 0.716, respectively). Conclusions Although the results show a reasonable diagnostic accuracy of these microRNAs for detection of breast cancer in this small and preliminary study, further large‐scale studies are essential to confirm the presented results.

show abstract

“…Unfortunately, these markers have low sensitivity and specificity for breast cancer screening. In recent years, aberrant expression of miRNAs has been widely reported in various carcinomas [14][15][16][17][18][19][20][21][22][23]. Half of all known miRNAs have been found in cancer-associated genomic regions or fragile locations, implying that they may have a role in the start and progression of human cancers [27].…”

Section: Discussionmentioning

confidence: 99%

“…miRNAs are thus potential early diagnostic biomarkers to detect breast cancer and monitor the treatment response of breast cancer patients. Among all uncovered miRNAs, miR-155 is no doubt one of the most attractive ones, which is reported to have potential diagnostic and prognostic value for cancers [14][15][16][17][18][19][20][21][22][23]. As the diagnostic role of miR-155 has not yet been well elucidated and has controversial results, however, we performed a comprehensive meta-analysis and estimated the pooled accuracy of miR-155 for cancer detection.…”

Section: Discussionmentioning

confidence: 99%